四烯甲萘醌(Menatetrenone) - 在研适应症：维生素K缺乏性出血，骨质疏松症，出血_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Menaquinone-4、Menatetrenone (JP17/INN)、VITAMIN-MK-4

+ [20]

靶点-

作用机制

骨生成刺激剂

治疗领域

遗传病与畸形内分泌与代谢疾病血液及淋巴系统疾病+ [4]

在研适应症

维生素K缺乏性出血骨质疏松症出血+ [5]

非在研适应症

肝细胞癌绝经期后骨质疏松

原研机构-

在研机构

Alfresa Pharma Corp.Japan National Hospital OrganizationSannova KK

+ [6]

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1972-06-29),

出血低凝血酶原血症

最高研发阶段(中国)无进展

特殊审评孤儿药 (美国)

登录后查看时间轴

结构

分子式C31H40O2

InChIKeyDKHGMERMDICWDU-GHDNBGIDSA-N

CAS号863-61-6

关联

47

项与四烯甲萘醌相关的临床试验

DRKS00034742 / SuspendedN/AIIT

Vitamin supplementation in cystic fibrosis in the era of modulators: the impact of vitamin K2 on cardio-metabolic health – a randomised double-blind placebo-controlled trial

开始日期2024-08-05

申办/合作机构-

ChiCTR2400081931 / SuspendedN/AIIT

The effect of vitamin K2 fortified nutritional intervention on muscle condition and clinical outcomes in elderly patients with muscle wasting syndrome

开始日期2024-03-19

申办/合作机构-

ChiCTR2400081953 / Recruiting临床1期IIT

A single-arm clinical trial study of the efficacy and safety of vitamin k2 in combination with a second-line standard regimen for the treatment of advanced hepatocellular carcinoma

开始日期2024-03-18

申办/合作机构

青岛大学附属医院

100 项与四烯甲萘醌相关的临床结果

登录后查看更多信息

100 项与四烯甲萘醌相关的转化医学

登录后查看更多信息

100 项与四烯甲萘醌相关的专利（医药）

登录后查看更多信息

1,403

项与四烯甲萘醌相关的文献（医药）

2024-12-01·FOOD MICROBIOLOGY

Soy protein hydrolysates induce menaquinone-7 biosynthesis by enhancing the biofilm formation of Bacillus subtilis natto

Article

作者: Yi, Yunxin ; Coldea, Teodora Emilia ; Chen, Moutong ; Zhao, Haifeng ; Yang, Huirong

Menaquinone-7 (MK-7) is a form of vitamin K₂ with health-beneficial effects. A novel fermentation strategy based on combining soy protein hydrolysates (SPHs) with biofilm-based fermentation was investigated to enhance menaquinone-7 (MK-7) biosynthesis by Bacillus subtilis natto. Results showed the SPHs increased MK-7 yield by 199.4% in two-stage aeration fermentation as compared to the SP-based medium in submerged fermentation, which was related to the formation of robust biofilm with wrinkles and the enhancement of cell viability. Moreover, there was a significant correlation between key genes related to MK-7 and biofilm synthesis, and the quorum sensing (QS) related genes, Spo0A and SinR, were downregulated by 0.64-fold and 0.39-fold respectively, which promoted biofilm matrix synthesis. Meanwhile, SPHs also enhanced the MK-7 precursor, isoprene side chain, supply, and MK-7 assembly efficiency. Improved fermentation performances of bacterial cells during fermentation were attributed to abundant oligopeptides (Mw < 1 kDa) and moderate amino acids, particularly Arg, Asp, and Phe in SPHs. All these results revealed that SPHs were a potential and superior nitrogen source for MK-7 production by Bacillus subtilis natto.

2024-11-01·BIORESOURCE TECHNOLOGY

Geranylgeraniol: Bio-based platform for teprenone, menaquinone-4, and α-tocotrienol synthesis

Article

By utilizing the conformational selectivity of biosynthesis and the flexibility of chemical synthesis, researchers have formulated metabolic engineering-based semi-synthetic approaches that initiate with the final product's structure and identify key biosynthesis intermediates. Nonetheless, these tailored semi-synthetic routes focused on end-products, neglecting the possibility of biobased intermediates as a platform for derivatization. To address this challenge, this studyproposed a novel strategy resembling chemosynthesis-style divergent exploration to amplify the significance of biobased intermediates, in the case of geranylgeraniol (GGOH). Using the novel bifunctional terpene synthase PTTC066 and systematic metabolic engineering modifications, the engineered yeast straindemonstrated high GGOH production levels (3.32 g/L, 0.039 g/L/h). This platformenabled the semi-synthesis of various pharmaceuticals, including the anti-ulcer drug teprenone, the osteoporosis treatment drug menaquinone-4, and introduced a novel route for synthesizingα-tocotrienol. This study offers a fresh outlook on semi-synthetic approaches, opening avenues for improvements, substitutions, and innovations in industrial production processes.

2024-11-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Vitamin K2 alleviates dextran sulfate sodium-induced colitis via inflammatory responses, gut barrier integrity, and the gut microbiota in mice

Article

作者: Li, Yinghao ; Zhan, Kai ; Liu, Zhen ; Liu, Yun ; Xu, Lei ; Wang, Huakai ; Ma, Qiugang

Vitamin K2 (VK2) has been shown to have potential benefits in improving intestinal integrity, but its potential and mechanisms for alleviating intestinal inflammation are still unclear. The present results showed that VK2 supplementation significantly alleviated the symptoms of colitis and maintained the intestinal barrier integrity. In addition, VK2 significantly down-regulated the mRNA expression levels of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α, while up-regulated the mRNA expression level of anti-inflammatory cytokines such as IL-10. Moreover, VK2 significantly alleviated DSS-induced intestinal epithelial barrier dysfunction by maintaining the tight junction function. Furthermore, VK2 also regulated DSS-induced gut microbiota dysbiosis by reshaping the structure of gut microbiota, such as increasing the relative abundance of Firmicutes, Euryarchaeota, Prevotellaceae, and Prevotella and reducing the relative abundance of Proteobacteria, Rikenellaceae, Enterobacteriaceae, Acetatifactor, and Alistioes. In conclusion, these results indicated that VK2 effectively alleviates DSS-induced colitis in mice by modulating the gut microbiota.

11

项与四烯甲萘醌相关的新闻（医药）

2024-01-23

·医药观澜

卫材宣布痛风治疗新药在中国申报上市

▎药明康德内容团队报道1月22日，卫材（Eisai）宣布多替诺雷片新药上市申请已获中国国家药监局药品审评中心（CDE）受理。多替诺雷片（dotinurad）是一款促尿酸排泄药，此前已经于2020年在日本获批用于治疗高尿酸血症和痛风。截图来源：CDE官网痛风是由单钠尿酸盐沉积在关节所致的晶体相关性关节病，目前中国的患病率为1% ~ 3%，并呈逐年上升趋势。痛风除了在急性发作期产生剧烈疼痛，对关节造成损害，还会伴发肾脏病变及其他代谢综合征的表现，如高脂血症、高血压、糖尿病和冠心病等。过高的血尿酸水平（即高尿酸血症）是发生痛风的重要危险因素。据卫材新闻稿介绍，多替诺雷是一种新型痛风治疗药物，通过选择性抑制与肾脏中尿酸重吸收有关的尿酸盐转运蛋白（URAT1），抑制尿酸重吸收并降低血尿酸水平。作为一种URAT1选择性抑制剂，该产品有效抑制肾近端小管URAT1而不影响尿酸排泄因子ABCG2和OAT1/3的功能，相比非选择性URAT1抑制剂降血尿酸的效率更高。公开资料显示，多替诺雷最初由富士药品（FUJI YAKUHIN）研发，卫材于2020年与富士药品达成许可协议，获得该产品在中国的独家开发和销售权。此前在日本开展的一项3期临床研究结果显示，多替诺雷4mg治疗伴或不伴痛风的高尿酸血症患者，58周血尿酸水平≤6mg的患者比例为100%，长期使用对肾功能无明显影响，对肝功能无临床相关影响。在中国，卫材开展了一项旨在评估多替诺雷和非布司他治疗痛风疗效的3期临床研究。该研究纳入451例痛风患者，随机分为多替诺雷4mg组和非布司他40mg组，主要研究终点是治疗24周血尿酸水平≤6.0mg/dL的患者百分比。根据卫材新闻稿，除了治疗痛风的新药多替诺雷，该公司在中国已上市的替普瑞酮胶囊、四烯甲萘醌软胶囊和雷贝拉唑钠肠溶片等药物，在风湿科、肾内科、骨科、内分泌科和心内科等多个领域发挥协同作用。多替诺雷的加入将丰富卫材中国在这些领域的产品管线，惠及广大患者。参考资料：[1]卫材治疗痛风新药「多替诺雷」在中国申报上市. Retrieved Jan 22，2024, From https://mp.weixin.qq.com/s/-X_9_97VxnNsh2xVjsMnlQ[2] 徐东, 等. 中华内科杂志. 2020,59(6):421-426.本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈。转发授权请在「医药观澜」微信公众号留言联系我们。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

临床3期申请上市临床结果

2024-01-22

·美通社

卫材治疗痛风新药「多替诺雷」在中国申报上市

今日（2024年1月22日），中国国家药品监督管理局药品审评中心（CDE）官网公示，卫材中国以注册分类5.1类申报的多替诺雷片上市申请已获得受理1。多替诺雷片（Dotinurad，商品名：优乐思）是一款促尿酸排泄药，此前已经于2020年在日本上市，用于治疗高尿酸血症和痛风2。痛风是由单钠尿酸盐沉积在关节所致的晶体相关性关节病，目前我国的患病率为1% ~ 3%，并呈逐年上升趋势。痛风除了在急性发作期产生剧烈疼痛，对关节造成损害，还会伴发肾脏病变及其他代谢综合征的表现，如高脂血症、高血压、糖尿病和冠心病等3。过高的血尿酸水平（即高尿酸血症）是发生痛风的最重要的危险因素4。多替诺雷是一种新型痛风治疗药物，通过选择性抑制与肾脏中尿酸重吸收有关的尿酸盐转运蛋白（URAT1），抑制尿酸重吸收并降低血尿酸水平5。作为一种URAT1选择性抑制剂，多替诺雷有效抑制肾近端小管URAT1而不影响尿酸排泄因子ABCG2和OAT1/3的功能，相比非选择性URAT1抑制剂降血尿酸的效率更高2。卫材在中国开展了一项旨在评估多替诺雷和非布司他治疗痛风疗效的3期临床研究（NCT05007392）。该研究纳入451例痛风患者，随机分为多替诺雷 4mg组和非布司他 40mg组，主要研究终点是治疗24周血尿酸水平≤ 6.0 mg/dL的患者百分比6。此前在日本开展的一项3期临床研究结果显示，多替诺雷 4mg治疗伴或不伴痛风的高尿酸血症患者，58周血尿酸水平≤ 6.0 mg/dL的患者达标率100%，长期使用对肾功能无明显影响，对肝功能无临床相关影响7。卫材中国始终将患者利益和公众健康放在首位，满足其多样化需求，为提升其福祉做出贡献。除了治疗痛风的新药多替诺雷，卫材中国已上市的施维舒®（替普瑞酮胶囊）、固力康®（四烯甲萘醌软胶囊）和波利特®（雷贝拉唑钠肠溶片）等多款药物在相关领域发挥协同作用。多替诺雷的加入将丰富卫材中国在这些领域的产品管线，惠及广大患者。参考资料： [1] 中国国家药监局药品审评中心（CDE）官网. [2] Ishikawa T, et al. Expert Opin Pharmacother. 2021,22(11):1397-1406. [3] 徐东, 等. 中华内科杂志. 2020,59(6):421-426. [4] Dalbeth N, et al. Lancet. 2021,397(10287):1843-1855. [5] 卫材中国. 2020-02-25 from https://mp.weixin.qq.com/s/CC5rg1feoMe0WVBR66t-_w [6] 美国临床试验注册库 from https://classic.clinicaltrials.gov/ct2/show/study/NCT05007392?term=dotinurad&cond=gout&draw=2&rank=1 [7] Hosoya T, et al. Clin Exp Nephrol. 2020;24(Suppl 1):80-91. 内容来源于网络，如有侵权，请联系删除。

申请上市临床结果

2024-01-04

·GlobeNewswire-Health Care

Healthy Extracts Launches First Anti-Aging Formulation, LONGEVITY

LAS VEGAS, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar nutraceuticals market, has launched LONGEVITY Anti-Aging™, a new proprietary formulation designed to support skin vitality, arterial flexibility, and cellular and joint health. LONGEVITY Anti-Aging is available to order today on BergametNA.com. In celebration of the launch, for a limited time you can buy two and get one free. You can also subscribe and save 15% on every order. The formulation is a special blend of the most powerful anti-aging warriors that include trans-resveratrol, quercetin, vitamin D, and vitamin K2. These substances are known to boost blood flow and circulation, reduce the deleterious effects of misplaced calcium in the body, and slow the effects of aging with powerful antioxidants. “LONGEVITY Anti-Aging complements our growing heart health product portfolio which supports a holistic approach to anti-aging like healthy skin,” noted Healthy Extracts president, Duke Pitts. “We anticipate this new product, along with the others we’re planning to launch early this year, will continue drive our growth and market expansion, as they leverage our multiple sales and distribution channels and existing customer base.” LONGEVITY Anti-Aging represents a holistic approach to aging, with a proprietary blend focused on providing the nutrition the body needs for optimal health. It is formulated to help sustain vitality, support heart health, ensure robust bone strength, and contribute to a healthier aging process. The formulation is vegan friendly, non-GMO, gluten-free, and produced and tested by certified U.S. facilities. Key substances and benefits: Trans-resveratrol and quercetin are powerful antioxidants that shield cells from aging and oxidative stress for more youthful function.Vitamin D and K2 are vital for proper calcium absorption and distribution, bolstering bone health and reducing osteoporosis risk.For heart health, ingredients like vitamin K2 and trans-resveratrol are key in maintaining cardiovascular wellness, helping to lower the risk of heart ailments.Vitamin D and quercetin also strengthens immune defense, enhancing protection against infection and disease. LONGEVITY Anti-Aging is your ally for overall longevity, blending ingredients renowned for their anti-aging benefits that support a longer, healthier life. LONGEVITY Anti-Aging introduction follows the recent official launch of BERGAMET SLEEP BREATHING SUPPORT™ , a natural supplement designed to support respiratory function for deeper, more restorative sleep. Given the better than anticipated initial sales of this new product, it is on track to become one of the company’s best sellers in 2024. Healthy Extracts’ full line of natural heart health formulations address the fast-growing, multi-billion dollar heart-health supplement market which is projected to grow at 5.9% CAGR to reach $24.8 billion by 2027, according to ResearchAndMarkets. To learn more about Healthy Extracts’ full line of clinically-backed, natural brain and hearth health products, go to bergametna.com or tryubn.com. About Healthy Extracts “Live Life Young Again” Healthy Extracts Inc. is a platform for acquiring, developing, researching, patenting, marketing, and distributing plant-based nutraceuticals. The company’s subsidiaries, BergametNA™ and Ultimate Brain Nutrients™ (UBN), offer nutraceutical natural heart and brain health supplements. This includes the only heart health supplement distributed in North America containing Citrus Bergamot SuperFruit™. This superfruit has the highest known concentration of polyphenols and flavonoids. UBN’s KETONOMICS® proprietary formulations, which have been designed to enhance brain activity, focus, headache and cognitive behavior, provide many sales and intellectual property licensing opportunities. For more information visit: healthyextractsinc.com, bergametna.com or tryubn.com. Forward-Looking Statements and Safe Harbor Notice All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on March 31, 2023, and future periodic reports filed with the SEC. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release. Food & Drug Administration Disclosure The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor’s advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. BergametNA™, Ultimate Brain Nutrients™, UBN™, Citrus Bergamot SuperFruit™ and F4T® are registered trademarks of Healthy Extracts Inc.™ Company ContactDuke Pitts, PresidentHealthy Extracts Inc.Tel (720) 463-1004Email contact Investor ContactRonald Both CMA Investor RelationsTel (949) 432-7566Email contactMedia Contact:Tim RandallCMA Media RelationsTel (949) 432-7572Email Contact A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/200b922a-c04a-45ab-b819-dba1b9750c42

上市批准

100 项与四烯甲萘醌相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00100	四烯甲萘醌	B02BA	DB12148

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
维生素K缺乏性出血	日本	Alfresa Pharma Corp.	2012-05-25
维生素K缺乏性出血	日本	Sannova KK	2012-05-25
骨质疏松症	日本	Eisai Co., Ltd.	1995-06-30
出血	日本	Eisai Co., Ltd.	1972-06-29
低凝血酶原血症	日本	Eisai Co., Ltd.	1972-06-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
绝经期后骨质疏松	临床3期	中国	Eisai Co., Ltd.	2005-05-01
肝细胞癌	临床3期	日本	Eisai Co., Ltd.	2004-03-01
脑出血	临床前	日本	Kumamoto University	2024-05-10
血管钙化	临床前	比利时	Nephrology Associates	2011-11-08
血管钙化	临床前	德国	Nephrology Associates	2011-11-08
白血病	临床前	日本	Tokyo Medical University	2007-11-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AVADEC (ESC2022)	N/A	冠心病	389	Vitamin K2 (720 μg/day) and Vitamin D (25 μg/day)	願膚壓顧簾衊糧積廠鹹(範鹽鏇艱構網選選積艱) = 願蓋蓋鬱鬱廠餘願襯網網廠繭壓觸壓醖獵壓餘 (襯鹽壓夢網簾鏇願鹽鏇 ) 更多	-	2022-08-28
				vitamin k2	願膚壓顧簾衊糧積廠鹹(範鹽鏇艱構網選選積艱) = 顧餘獵糧鹽觸遞觸壓窪網廠繭壓觸壓醖獵壓餘 (襯鹽壓夢網簾鏇願鹽鏇 ) 更多
MO789 (ERA2022)	N/A	matrix Gla protein (MGP)	120	Vitamin K1	觸網鬱願網襯窪構鹹壓(窪襯築選範獵選淵製獵) = 鏇鑰鑰網選艱憲製構淵壓襯築憲壓鏇憲淵夢夢 (齋鑰窪淵遞顧窪鑰製築 )	积极	2022-05-03
				Vitamin K2	觸網鬱願網襯窪構鹹壓(窪襯築選範獵選淵製獵) = 鏇構鹽選鹹鏇醖鬱淵鹹壓襯築憲壓鏇憲淵夢夢 (齋鑰窪淵遞顧窪鑰製築 )
Pubmed \| J Am Coll Cardiol	N/A	主动脉瓣钙化	365	MK-7 plus vitamin D	遞鑰齋餘選齋窪願壓齋(齋廠遞鏇顧鏇襯鑰餘獵) = 鹽範遞憲憲鏇獵鑰鹹範鏇鹽鑰構壓築製觸餘鏇 (鹽艱願築壓窪製網廠壓, 225 ~ 326) 更多	-	2022-04-25
				Vitamin K2 (Placebo)	遞鑰齋餘選齋窪願壓齋(齋廠遞鏇顧鏇襯鑰餘獵) = 構廠鬱齋繭齋糧範窪醖鏇鹽鑰構壓築製觸餘鏇 (鹽艱願築壓窪製網廠壓, 246 ~ 338) 更多
FP608 (ERA2019)	N/A	血管钙化 uncarboxylated-MGP	102	Vitamin K2 supplementation (200μg/day)	艱夢製選窪夢構齋遞艱(鬱願繭窪餘餘顧膚淵窪) = 衊願蓋醖蓋築憲齋鑰顧鹹艱簾積顧鏇衊鏇壓簾 (淵夢鏇膚衊襯鹽願觸顧 ) 更多	不佳	2019-06-13
				Vitamin K2	艱夢製選窪夢構齋遞艱(鬱願繭窪餘餘顧膚淵窪) = 鏇鑰顧觸憲齋餘鹽夢鹹鹹艱簾積顧鏇衊鏇壓簾 (淵夢鏇膚衊襯鹽願觸顧 ) 更多
NCT02876354 (Pubmed \| BMC Nephrol)	临床4期	血液透析并发症	50	Vitamin K2 (menaquinone-7)	膚鏇窪夢衊夢艱鑰壓鹽(衊積淵築廠鏇糧鏇醖遞) = 築簾衊鏇遞鏇醖製顧襯範淵鹹鹽鬱襯夢繭壓積 (壓淵衊繭構獵鑰願顧艱 )	-	2017-06-07
NCT02876354 (MO021, ERA2017)	临床4期	血液透析并发症 dp-ucMGP \| MGP \| vitamin K2	50	Vitamin K2 (menaquinone-7)	範糧顧顧淵鹽窪蓋顧襯(構衊餘蓋製壓鏇積夢憲) = 鏇窪選選壓蓋衊夢觸鏇製憲襯鹹願艱襯鏇鑰獵 (製繭範觸餘壓簾獵艱襯 )	积极	2017-05-26
NCT04247087 \| NCT01101698 (Pubmed)	临床4期	慢性肾病	42	Vitamin K2 + cholecalciferol (K+D)	積淵範膚窪淵觸築壓醖(繭遞憲鹽糧夢蓋範齋鹽) = 壓網觸製壓獵構製醖鹹膚蓋鏇築餘鹹蓋鬱餘願 (齋齋鹹醖窪壓壓窪積鹽 )	-	2015-01-01
				Cholecalciferol (D)	積淵範膚窪淵觸築壓醖(繭遞憲鹽糧夢蓋範齋鹽) = 願範簾壓顧齋膚衊鏇顧膚蓋鏇築餘鹹蓋鬱餘願 (齋齋鹹醖窪壓壓窪積鹽 )
SP230 (ERA2014)	N/A	慢性肾病 dp-ucMGP positive \| MGP positive \| osteocalcin	42	Vitamin K2 (menaquinone-7, MK-7) + cholecalciferol	觸鹽構鑰廠夢膚鬱簾鏇(鑰淵積蓋鏇觸憲夢製鬱) = 繭蓋衊築鏇衊築壓衊艱鏇糧憲艱顧膚積鹹網鏇 (繭糧簾積壓齋築獵繭簾, 1077.1±507.7) 更多	积极	2014-05-01
				Vitamin D	觸鹽構鑰廠夢膚鬱簾鏇(鑰淵積蓋鏇觸憲夢製鬱) = 願簾構願壓積淵餘齋餘鏇糧憲艱顧膚積鹹網鏇 (繭糧簾積壓齋築獵繭簾, 793.9±400.3) 更多
Pubmed \| Nutr J	N/A	-	-	Menaquinone-4 (MK-4)	製糧齋網蓋廠廠憲鏇膚(夢遞鹹夢構廠夢製積構) = 製膚繭蓋窪製窪壓網築醖選選簾醖淵鑰餘簾築 (廠膚淵積廠觸醖窪餘繭 )	-	2012-12-01
ASN2012	N/A	dp-uc-MGP	200	Vitamin K2 360 µg	餘醖築醖艱觸觸夢糧鹽(膚鹹顧鬱鬱願夢構製窪) = 13% of patients suffered from gastro-intestinal side effects, unrelated to the dose. Nausea caused by the unpleasant smell of the uncoated tablets was reported most frequent. 遞築積積糧齋觸淵遞齋 (齋壓夢衊範糧壓蓋顧衊 )	积极	2012-10-30
				Vitamin K2 720 µg